{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-malignant-skin-ulcer/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"cce56ef7-baec-5a1f-9927-a88b697e0b79","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 4122561d-eebf-41e4-93ed-92f0d2209857 --><h2>Metronidazole</h2><!-- end field 4122561d-eebf-41e4-93ed-92f0d2209857 -->","summary":"","htmlStringContent":"<!-- begin item dc2d8f0a-5cad-4850-bd08-1dc21385799f --><!-- end item dc2d8f0a-5cad-4850-bd08-1dc21385799f -->","topic":{"id":"a66236f8-759a-578d-b8e0-d9b9f4d4b17b","topicId":"594ae15d-e8a6-49e1-9bc4-b8235684b211","topicName":"Palliative care - malignant skin ulcer","slug":"palliative-care-malignant-skin-ulcer","lastRevised":"Last revised in October 2018","chapters":[{"id":"8aae23f3-652c-5220-96a9-570f5c6a4197","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3fae4ef2-1de8-537a-8d87-bb0f0e925ca2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7cd1b72b-f0ca-5fa9-a739-760c7315a4c6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"28f3598f-1a0b-5fa6-885c-7908290eef3d","slug":"changes","fullItemName":"Changes"},{"id":"ee67bddb-c899-5cdf-8bd4-b6ce53a64863","slug":"update","fullItemName":"Update"}]},{"id":"7209a66f-e985-5a26-b178-2d841634478d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a512b109-ae33-58f1-9b3e-1bb25ba17ed1","slug":"goals","fullItemName":"Goals"},{"id":"d4f96da2-1dfd-5b18-aeec-d33fe0b56967","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ec220b93-2051-5b93-ada7-66029759c688","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e8a03776-8e6f-57f0-9d78-72e639758d72","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a89f6107-4d65-56f2-a108-583acc3aa1dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99d9f654-11a9-5749-882a-6bfac0a995ad","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba712e36-e31f-53bb-9746-10f4bb36e7e9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ae192ef-3ead-55f6-b5dc-e15c6fbe8e92","slug":"definition","fullItemName":"Definition"},{"id":"6045e3e4-960f-5f2a-949e-66eaa7d7fd27","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fb13b65f-08f4-5ac4-b21a-bbba9bec2bce","slug":"complications","fullItemName":"Complications"}]},{"id":"5750038d-2dca-5b1b-9cef-5ec97727cd6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"576c0eda-301a-5d5f-9d9f-34505854cac8","slug":"palliative-cancer-care-malignant-skin-ulcer","fullItemName":"Scenario: Palliative cancer care - malignant skin ulcer"},{"id":"4c917ea3-8a66-5e50-9cd2-a4494533a824","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"c6fd3a21-3f33-5f10-9f9b-22da77001d52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"cce56ef7-baec-5a1f-9927-a88b697e0b79","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"6fb5a8ca-5e8b-5cea-9647-c8d15aa9fd31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c16178c4-497b-57f0-8903-94f79dc3e888","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0676abc6-76ab-5fcf-816a-0f0fd3c08737","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7c58ec18-ffff-5082-9660-ff776be47414","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"ec9b77b3-9f46-5d3d-89fe-1d2ba54e8e03","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b921fab-b857-5da1-90cd-616aa087e15a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f5f487fa-4ace-58e9-aefa-a01924f86557","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0a5cfba7-db2d-58b1-b705-aef0029b384e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c6fd3a21-3f33-5f10-9f9b-22da77001d52","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"744463bf-0a01-58ab-88cd-0f0a3385462f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1d9160a2-1d6c-4e9d-915b-c540e3e80f6e --><h3>Contraindications and cautions</h3><!-- end field 1d9160a2-1d6c-4e9d-915b-c540e3e80f6e -->","summary":"","htmlStringContent":"<!-- begin item 83cb51f1-a760-4a38-a1e7-daee4e6f82a1 --><!-- begin field 09e8026b-4e2d-4814-adc3-d5907711d162 --><p><strong>Metronidazole is contraindicated in people with known hypersensitivity to nitroimidazoles </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>]<strong>.</strong></p><p><strong>Do not prescribe metronidazole to a person with:</strong></p><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole. </li></ul><p><strong>Prescribe oral metronidazole with caution</strong><strong>:</strong></p><ul><li>In people with active or chronic severe peripheral and central nervous system disease, due to the risk of neurological aggravation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li><li>In people with severe liver disease and hepatic encephalopathy, due to substantial impairment of metronidazole clearance. The daily dosage should be reduced to one-third and may be administered once daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">BNF 72, 2016</a>].</li><li>For prolonged use, as prolonged therapy may be associated with peripheral neuropathy or leucopenia. Both effects are usually reversible. It is recommended that a full blood count be carried out regularly and that people should be monitored for adverse reactions such as peripheral or central neuropathy (including paraesthesia, ataxia, dizziness, or convulsive seizures) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li></ul><p><strong>Prescribe </strong><strong>topical metronidazole with caution:</strong></p><ul><li>Near the eyes as it can cause lacrimation, contact with the eyes should be avoided.</li><li>In areas exposed to direct sunlight as it is inactivated by ultraviolet light exposure. Treatment sites should not be exposed to strong sunlight [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].</li></ul><!-- end field 09e8026b-4e2d-4814-adc3-d5907711d162 --><!-- end item 83cb51f1-a760-4a38-a1e7-daee4e6f82a1 -->","subChapters":[]},{"id":"0e6a3d32-2025-5ed7-955a-13e91f81d330","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ddd03446-90e9-436d-97d9-d8fa52d397c1 --><h3>Drug interactions</h3><!-- end field ddd03446-90e9-436d-97d9-d8fa52d397c1 -->","summary":"","htmlStringContent":"<!-- begin item 0d3586c9-b7a3-4265-9b5b-e11158a06dab --><!-- begin field 4f53e99c-4586-4a5d-aebd-a22c0557c1b8 --><p><strong>Important drug interactions associated with oral metronidazole include:</strong></p><ul><li><strong>Alcohol </strong>— some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst taking metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">BNF 72, 2016</a>]. Alcohol should be avoided for 24–48 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter, 2013</a>].</li></ul></li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].<ul><li>Monitor the international normalized ratio (INR) if metronidazole is given with warfarin and adjust the warfarin dose accordingly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter, 2013</a>].</li><li>Warn the person of the possible risk of increased bruising and bleeding. Advise when to seek medical help.</li></ul></li><li><strong>Ciclosporin </strong>— the Summary of Product Characteristics (SPC) states that when co-administration of metronidazole and ciclosporin are necessary serum ciclosporin and creatinine should be closely monitored [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li><li><strong>Lithium </strong>— seek expert advice regarding the concurrent use of metronidazole and lithium as lithium dose adjustments may be required. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored in people being treated with lithium while receiving metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li><li><strong>Contraceptives </strong>— additional contraceptive precautions are <em>not </em>required during or after courses of metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">FSRH, 2011</a>].<ul><li>Advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p><strong>Drug interactions associated with topical metronidazole:</strong></p><ul><li>Interactions with systemic medication is reported as unlikely due to the limited absorption when administered topically.</li><li>A disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol is reported in a small number of people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst taking metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">BNF 72, 2016</a>]. Alcohol should be avoided for 24–48 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Baxter, 2013</a>].</li></ul></li><li>Very rare cases of modification of the INR with topical metronidazole and warfarin have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].</li></ul><!-- end field 4f53e99c-4586-4a5d-aebd-a22c0557c1b8 --><!-- end item 0d3586c9-b7a3-4265-9b5b-e11158a06dab -->","subChapters":[]},{"id":"6ab49765-adef-5aaf-a411-09d1cb3bc3fd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 208b45cb-3413-4e5e-a007-66bafba7f613 --><h3>Adverse effects</h3><!-- end field 208b45cb-3413-4e5e-a007-66bafba7f613 -->","summary":"","htmlStringContent":"<!-- begin item e752ee54-dc72-4cdc-b00c-cdca35978de1 --><!-- begin field b004b173-4ad3-4a97-a36b-a2ec8b637370 --><h4>Oral metronidazole</h4><ul><li>Gastrointestinal disturbances (including nausea and vomiting), taste disturbances, furred tongue, oral mucositis, anorexia; very rarely hepatitis, jaundice, pancreatitis, drowsiness, dizziness, headache, ataxia, psychotic disorders, darkening of urine, thrombocytopenia, pancytopenia, myalgia, arthralgia, visual disturbances, rash, pruritis, and erythema multiforme [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">BNF 72, 2016</a>].</li><li>Warn people about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions, or transient visual disorders. Advise them not to drive or operate machinery if these symptoms occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><h4>Topical metronidazole</h4><ul><li>Topical metronidazole has fewer systemic adverse effects compared to oral metronidazole, but may sting on application [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Wilson, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">McDonald and Lesage, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Alvarez et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Leicester County and Rutland PCT, 2009</a>]. This may be avoided by prescribing a cream formulation (off-label) as the stinging may be due to the presence of alcohol in the gel formulation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">Alvarez et al, 2007</a>].</li><li>Lacrimation has been reported if topical metronidazole is applied too close to the eye area [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].</li><li>Exposure of treated sites to ultraviolet (UV) radiation (such as bright sunlight) should be avoided as it is inactivated by UV exposure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].</li></ul><!-- end field b004b173-4ad3-4a97-a36b-a2ec8b637370 --><!-- end item e752ee54-dc72-4cdc-b00c-cdca35978de1 -->","subChapters":[]},{"id":"05f0b322-726a-5f73-9dee-03aed3ea610d","slug":"pregnancy-or-breastfeeding","fullItemName":"Pregnancy or breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8d9e7f85-70b7-4762-af67-d0eb6663945d --><h3>Pregnancy or breastfeeding</h3><!-- end field 8d9e7f85-70b7-4762-af67-d0eb6663945d -->","summary":"","htmlStringContent":"<!-- begin item cf68911f-5b3f-4349-a8d2-a409bc07b0f6 --><!-- begin field caff747f-958c-4e66-9b10-0bfed6af32f3 --><h4>Oral metronidazole</h4><ul><li>The Summary of Product Characteristics (SPC) states that oral metronidazole has been in wide use for many years without clinical issues. However, it states it should not be given during pregnancy or breastfeeding unless essential, and short, high-dose regimes are not recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2014</a>].</li></ul><h4>Topical metronidazole</h4><ul><li>The SPC states that there is no safety data regarding the use of topical metronidazole in pregnancy. Blood levels are significantly lower than those from oral metronidazole, but a clinical decision is recommended regarding balancing the risks and benefits of treatment during breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">ABPI Medicines Compendium, 2015</a>].</li></ul><!-- end field caff747f-958c-4e66-9b10-0bfed6af32f3 --><!-- end item cf68911f-5b3f-4349-a8d2-a409bc07b0f6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}